|
Multiple Myeloma
|
0.200 |
Biomarker
|
disease |
BEFREE |
The International Staging System (ISS) -calculated from serum albumin and beta-2 microglobulin (β2m)- is an established prognostic marker in multiple myeloma (MM), which has also been suggested to account for survival among general senior population.
|
31387843 |
2019 |
|
Multiple Myeloma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Results showed that 8.3% of patients with MM were detected with del(1p32.3) and had significantly more bone marrow plasma cells (P = 0.025), higher β2-microglobulin levels (P = 0.036), and higher lactate dehydrogenase levels (P = 0.042) than those without del(1p32.3).
|
31784918 |
2019 |
|
Multiple Myeloma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Circ-AMARCA5 was downregulated in MM and presented a good value in distinguishing MM patients from controls and it was also negatively correlated with Beta-2-microglobulin (β2-MG) level and International Staging System (ISS) stage.
|
31601173 |
2019 |
|
Multiple Myeloma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Beta-2-microglobulin is a serum marker of tumor burden in multiple myeloma (MM).
|
31762076 |
2019 |
|
Multiple Myeloma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Our data showed that the median serum PF4 concentration was negatively associated with MM response and a significant correlation between serum PF4 level and unfavorable clinical features (β2-microglobulin, ISS stage, del17p and creatinine).
|
30890040 |
2019 |
|
Multiple Myeloma
|
0.200 |
Biomarker
|
disease |
BEFREE |
NT-proBNP showed a highly significant positive correlation with B2M at first presentation [r = .65, P < .001] and increased significantly with progressing MM disease stage [133.3 pg/mL (IQR:51.5-282.0) for ISS stage 1, 487.4 pg/mL (IQR:123.8-738.3) for ISS stage 2 and 969.1 pg/mL (IQR:472.8-3748.0) for ISS stage 3, P < .001 between all groups].
|
29417568 |
2018 |
|
Multiple Myeloma
|
0.200 |
Biomarker
|
disease |
BEFREE |
The recently introduced Revised International Staging System (R-ISS) for multiple myeloma (MM) integrates albumin, β2 microglobulin, lactate dehydrogenase (LDH) with high-risk cytogenetic aberrations (CA), i.e., t(4;14) and t(14;16) and del17p using fluorescent in situ hybridization (FISH).
|
30056581 |
2018 |
|
Multiple Myeloma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
In the two determinants, β2-microglobulin levels are frequently observed to be elevated in patients with myeloma, particularly in those with renal impairment.
|
30176173 |
2018 |
|
Multiple Myeloma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
MM patients with EBNA-1-specific mc IgG (14.0%) showed substantially greater bone marrow plasma cell infiltration and higher β2-microglobulin and inflammation/infection-linked cytokine levels compared with other smoldering myeloma/MM patients.
|
28978808 |
2017 |
|
Multiple Myeloma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Clustering of Δ13, del(17)(p13.1) and IgH translocations in non-hyperdiploidy confirmed prognostic significance of ploidy in MM. t(4;14) and del(17)(p13.1) were high-risk groups due to correlation with high serum β2-microglobulin, increased plasma cells and advanced disease.
|
28256461 |
2016 |
|
Multiple Myeloma
|
0.200 |
GeneticVariation
|
disease |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
Multiple Myeloma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
β2 microglobulin level in MM positively correlated with the number of PCs and negatively with percentage of naive B-cells (P < .05).
|
25578543 |
2015 |
|
Multiple Myeloma
|
0.200 |
Biomarker
|
disease |
BEFREE |
The value of OPN was significantly higher in MM patients with evident bone lesions (P = 0.03) and there was also a positive correlation with serum beta-2 microglobulin (r = 0.366; P = 0.04).
|
24995304 |
2014 |
|
Multiple Myeloma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
In MM, the correlation of gene expression profiles with clinical characteristics highlighted POT1 for its significant association with advanced clinical stages, high calcium and β2-microglobulin levels (p=0.02) and bone lesions (p=0.009).
|
24239198 |
2014 |
|
Multiple Myeloma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Finally, linear correlation analysis of the Lactate Dehydrogenase concentration and beta 2-microglobulin level with BLyS, and expressions of BLyS mRNA in MM patients revealed a significant correlation between them (P < 0.01 in all case), showing that BLyS could be a biomarker for the diagnosis and treatment of MM.
|
19187273 |
2009 |
|
Multiple Myeloma
|
0.200 |
AlteredExpression
|
disease |
LHGDN |
Beta-2-microglobulin level predicts outcome following autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
|
18022010 |
2007 |
|
Multiple Myeloma
|
0.200 |
Biomarker
|
disease |
BEFREE |
The current most powerful prognostic model in Multiple Myeloma (MM) combines beta-2 microglobulin (b2m) with albumin, corresponding to the International Staging System (ISS).
|
17692103 |
2007 |
|
Multiple Myeloma
|
0.200 |
Biomarker
|
disease |
BEFREE |
We discovered that monoclonal antibodies (mAbs) specific to human beta(2)-microglobulin (beta(2)M) induce apoptosis in vitro and were therapeutic in mouse models of myeloma and other hematological tumor cells.
|
17045207 |
2006 |
|
Multiple Myeloma
|
0.200 |
Biomarker
|
disease |
LHGDN |
Comparison of serum beta 2-microglobulin and 24 hour urinary creatinine clearance as a prognostic factor in multiple myeloma.
|
16891806 |
2006 |
|
Multiple Myeloma
|
0.200 |
Biomarker
|
disease |
BEFREE |
The positive correlation between MIP-1alpha and beta(2)-microglobulin that has been observed in MM patients at diagnosis further supports the notion that MIP-1alpha is not only a chemokine with osteoclast activity function but is also implicated in myeloma growth and survival.
|
16263571 |
2005 |
|
Multiple Myeloma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
High-risk features are, first and foremost, the detection of unfavorable cytogenetic abnormalities (chromosome 13 deletion, hypodiploidy and myelodysplastic-type abnormalities in an otherwise typical myeloma karyotype) prior to treatment; elevated serum lactate dehydrogenase and C-reactive protein levels at diagnosis and high beta-2 microglobulin levels prior to transplant also convey poor prognosis, although they account for less variability of the observed outcome than the cytogenetic abnormalities.
|
15359986 |
2004 |
|
Multiple Myeloma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
Systematic research at University of Arkansas over the last 10 years, has revealed that the absence of unfavorable cytogenetic abnormalities (deletion of chromosome 13 and hypodiploidy), low beta-2 microglobulin levels prior to transplant, a normal lactate dehydrogenase level at diagnosis and early application of high-dose treatment (< 12 months of preceding standard treatment) define a subgroup of myeloma patients with a high likelihood of long (> 5 years) event-free survival; a sizable minority of these patients may be considered cured.
|
12802910 |
2003 |
|
Multiple Myeloma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Patients with abnormalities were more likely to have features of aggressive disease as compared to all other patients without abnormalities entered into the myeloma database (lower hemoglobin, higher beta(2)-microglobulin, labeling-index and plasmocytosis; all P < 0.0001).
|
12592343 |
2003 |
|
Multiple Myeloma
|
0.200 |
Biomarker
|
disease |
BEFREE |
Cytogenetics play a dominant role in myeloma and were independent of previously recognized important prognostic factors, such as B2M and duration of prior standard therapy.
|
9215838 |
1997 |
|
Multiple Myeloma
|
0.200 |
AlteredExpression
|
disease |
BEFREE |
MDR positivity was not found in micromolecular MM and was significantly associated with the serum beta 2-microglobulin level.
|
8767528 |
1996 |